It is no longer a question of whether antiplatelet therapy should be used following implantation of a drug-eluting stent, but rather to what extent and to what duration. With this in mind, many new challenges arise, from bleeding risks to drug intolerance and product cost. Host Dr. Doug Weaver welcomes Dr. Peter Berger, associate chief research officer and director of the Center for Clinical Studies at the Geisinger Clinic in central Pennsylvania, to discuss how we’re moving to address these concerns. Dr. Berger also details a series of related procedural circumstances—dental surgery, bronchoscopy, certain orthopaedic procedures and more—in which antiplatelet therapy need not be discontinued.